Beyond Conventional Considerations: Newer Devices Used in Blood Pressure Measurement and Management

  • Raymond R. Townsend
    Address correspondence to Raymond R. Townsend, MD, Renal Division, University of Pennsylvania, 3400 Spruce Street, 122 Founders Building, Philadelphia, PA 19104.
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA; and Renal Division, University of Pennsylvania, Philadelphia, PA
    Search for articles by this author
  • Domenic A. Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA; and Renal Division, University of Pennsylvania, Philadelphia, PA
    Search for articles by this author
      Several noninvasive devices are now available to assess blood vessel structure and function and have been shown in longitudinal cohort studies to provide additional cardiovascular event prediction over that obtained by conventional brachial blood pressure (BP) measurements. Among these newer measurements are estimates of vascular stiffness (as determined by the pulse wave velocity in the aorta) and measures of pulse wave reflection. Pulse wave velocity, in particular, has been well studied in end-stage kidney (ESKD) populations where it predicts cardiovascular events and death independently of standard BP. In addition, there are minimum 3 devices, either marketed or used in clinical trials, that are useful in some clinical situations as an adjunct to drug therapy for managing high BP. This review will focus on the roles of these new technologies in evaluating and managing high BP, emphasizing the CKD/ESKD patient where possible, although data are limited in the kidney disease population when it comes to managing BP with these novel device approaches.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pannier B.
        • Guerin A.P.
        • Marchais S.J.
        • et al.
        Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients.
        Hypertension. 2005; 45: 592-596
        • Bramwell J.C.
        • Hill A.V.
        The velocity of the pulse wave in man.
        Proc Soc Lond (Biol). 1922; 93: 298-306
        • Guerin A.P.
        • Blacher J.
        • Pannier B.
        • et al.
        Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.
        Circulation. 2001; 103: 987-992
      1. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: “Establishing normal and reference values.”.
        Eur Heart J. 2010; 31: 2338-2350
        • Martyn C.N.
        • Greenwald S.E.
        Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension.
        Lancet. 1997; 350: 953-955
        • Harkness M.L.
        • Harkness R.D.
        • McDonald D.A.
        The collagen and elastin content of the arterial wall in the dog.
        Proc R Soc Lond B Biol Sci. 1957; 146: 541-551
        • Bank A.J.
        • Wang H.
        • Holte J.E.
        • et al.
        Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus.
        Circulation. 1996; 94: 3263-3270
        • London G.M.
        • Marchais S.J.
        • Guerin A.P.
        • et al.
        Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
        Kidney Int Suppl. 2003; 84: S88-S93
        • Vlachopoulos C.
        • Hirata K.
        • O’Rourke M.F.
        Effect of sildenafil on arterial stiffness and wave reflection.
        Vasc Med. 2003; 8: 243-248
        • Wilkinson I.B.
        • MacCallum H.
        • Hupperetz P.C.
        • et al.
        Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man.
        J Physiol. 2001; 530: 541-550
        • Townsend R.R.
        • Wimmer N.J.
        • Chirinos J.A.
        • et al.
        Aortic PWV in chronic kidney disease: a CRIC ancillary study.
        Am J Hypertens. 2010; 23: 282-289
        • Vlachopoulos C.
        • Aznaouridis K.
        • Stefanadis C.
        Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.
        J Am Coll Cardiol. 2010; 55: 1318-1327
        • Moser M.
        • Hebert P.
        • Hennekens C.H.
        An overview of the meta-analyses of the hypertension treatment trials.
        J Am Coll Cardiol. 1996; 151: 1277-1279
        • Law M.R.
        • Morris J.K.
        • Wald N.J.
        Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
        BMJ. 2009; 338: 1245-1253
        • Jamerson K.
        • Weber M.A.
        • Bakris G.L.
        • et al.
        Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
        N Engl J Med. 2008; 359: 2417-2428
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • et al.
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • McEniery C.M.
        • Yasmin McDonnell B.
        • et al.
        Central pressure: variability and impact of cardiovascular risk factors.
        The Anglo-Cardiff Collaborative Trial II. Hypertension. 2008; 51: 1476-1482
        • Katakam R.
        • Townsend R.R.
        What’s in a pulse?.
        J Clin Hypertens (Greenwich). 2006; 8: 140-141
        • Mitchell G.F.
        Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage.
        J Appl Physiol. 2008; 105: 1652-1660
        • Katakam R.
        • Townsend R.R.
        What’s in a pulse? Part 2.
        J Clin Hypertens (Greenwich). 2006; 8: 288-290
        • McEniery C.M.
        • Yasmin Hall IR.
        • et al.
        Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT).
        J Am Coll Cardiol. 2005; 46: 1753-1760
        • Laurent S.
        • Cockcroft J.
        • Van Bortel L.
        • et al.
        Expert consensus document on arterial stiffness: methodological issues and clinical applications.
        Eur Heart J. 2006; 27: 2588-2605
        • Vlachopoulos C.
        • Aznaouridis K.
        • O’Rourke M.F.
        • et al.
        Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis.
        Eur Heart J. 2010; 31: 1819-1822
        • Takenaka T.
        • Mimura T.
        • Kanno Y.
        • et al.
        Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases.
        Am J Nephrol. 2005; 25: 417-424
        • Taal M.W.
        • Sigrist M.K.
        • Fakis A.
        • et al.
        Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5.
        Nephron Clin Pract. 2007; 107: c177-c181
        • Safar M.E.
        • Blacher J.
        • Pannier B.
        • et al.
        Central pulse pressure and mortality in end-stage renal disease.
        Hypertension. 2002; 39: 735-738
        • Eddington H.
        • Sinha S.
        • Li E.
        • et al.
        Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study.
        Nephron Clin Pract. 2009; 112: c190-c198
        • Hermans M.M.
        • Henry R.
        • Dekker J.M.
        • et al.
        Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study.
        J Am Soc Nephrol. 2007; 18: 1942-1952
        • Pramanik T.
        • Sharma H.O.
        • Mishra S.
        • et al.
        Immediate effect of slow pace bhastrika pranayama on blood pressure and heart rate.
        J Altern Complement Med. 2009; 15: 293-295
        • Nidich S.I.
        • Rainforth M.V.
        • Haaga D.A.
        • et al.
        A randomized controlled trial on effects of the transcendental meditation program on blood pressure, psychological distress, and coping in young adults.
        Am J Hypertens. 2009; 22: 1326-1331
        • Oneda B.
        • Ortega K.C.
        • Gusmao J.L.
        • et al.
        Sympathetic nerve activity is decreased during device-guided slow breathing.
        Hypertens Res. 2010; 33: 708-712
      2. Resperate for hypertension.
        Med Lett Drugs Ther. 2007; 49: 55-56
      3. RESPeRATE. Available at: Accessed November 2, 2010.

        • Parati G.
        • Carretta R.
        Device-guided slow breathing as a non-pharmacological approach to antihypertensive treatment: efficacy, problems and perspectives.
        J Hypertens. 2007; 25: 57-61
        • Lohmeier T.E.
        The sympathetic nervous system and long-term blood pressure regulation.
        Am J Hypertens. 2001; 14: 147S-154S
        • Elliott W.J.
        • Izzo Jr., J.L.
        • White W.B.
        • et al.
        Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing.
        J Clin Hypertens (Greenwich). 2004; 6: 553-559
        • Schwartz S.I.
        • Griffith L.S.
        • Neistadt A.
        • et al.
        Chronic carotid sinus nerve stimulation in the treatment of essential hypertension.
        Am J Surg. 1967; 114: 5-15
        • Sica D.A.
        • Lohmeier T.E.
        Baroreflex activation for the treatment of hypertension: principles and practice.
        Expert Rev Med Devices. 2006; 3: 595-601
        • Scheffers I.J.
        • Kroon A.A.
        • Tordoir J.H.
        • et al.
        Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension.
        Expert Rev Med Devices. 2008; 5: 33-39
        • Illig K.A.
        • Levy M.
        • Sanchez L.
        • et al.
        An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.
        J Vasc Surg. 2006; 44: 1213-1218
        • Scheffers I.J.
        • Kroon A.A.
        • Schmidli J.
        • et al.
        Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
        J Am Coll Cardiol. 2010; 56: 1254-1258
        • Sica D.A.
        • Bakris G.
        • Bisognano J.
        • et al.
        A phase III trial of barareflex activation therapy for resistant hypertension: trial design and baseline characteristics of the Rheos Pivotal Trial [abstract].
        J Clin Hypertens. 2010; 12 (A-114)
        • Bakris G.
        • Bisognano J.
        • Nadim M.
        • et al.
        Achievement of blood pressure goal in patients with resistant hypertension treated with baroreflex activation therapy(R) [abstract].
        J Hypertens. 2010; 28: e282
        • Converse Jr., R.L.
        • Jacobsen T.L.
        • Toto R.D.
        • et al.
        Sympathetic overactivity in patients with chronic renal failure.
        N Engl J Med. 1992; 327: 1912-1918
        • Krum H.
        • Schlaich M.
        • Whitbourn R.
        • et al.
        Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
        Lancet. 2009; 373: 1275-1281
        • Schlaich M.P.
        • Sobotka P.A.
        • Krum H.
        • et al.
        Renal sympathetic-nerve ablation for uncontrolled hypertension.
        N Engl J Med. 2009; 361: 932-934
        • Appel L.J.
        • Wright Jr., J.T.
        • Greene T.
        • et al.
        Intensive blood-pressure control in hypertensive chronic kidney disease.
        N Engl J Med. 2010; 363: 918-929